Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Sanofi downgraded to Hold from Buy at Liberum (earlier) » 10:47
01/22/20
01/22
10:47
01/22/20
10:47
SNY

Sanofi

$49.61 /

-0.62 (-1.23%)

, AZN

AstraZeneca

$50.85 /

+0.055 (+0.11%)

, NVS

Novartis

$95.17 /

-0.035 (-0.04%)

Liberum analyst Alistair…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Bloomberg to hold a conference » 08:45
01/22/20
01/22
08:45
01/22/20
08:45
IBM

IBM

$139.15 /

+0.84 (+0.61%)

, LNKD

Acquired by MSFT

$0.00 /

+ (+0.00%)

, NVS

Novartis

$95.21 /

-0.725 (-0.76%)

The Year Ahead:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Regeneron price target raised to $450 from $430 at Oppenheimer » 08:18
01/22/20
01/22
08:18
01/22/20
08:18
REGN

Regeneron

$363.74 /

-22.01 (-5.71%)

, SNY

Sanofi

$50.23 /

-0.975 (-1.90%)

Oppenheimer analyst…

Oppenheimer analyst Hartaj Singh raised his price target for Regeneron (REGN) to $450 from $430 after meeting with management and receiving a "surprisingly positive update." The abating of Eylea competitive dynamics, a strong end to 2019, an intensified focus on Dupixent by the new CEO at partner Sanofi (SNY), a simplification of the Sanofi/Regeneron antibody agreement that could be accretive in 2020, a burgeoning internally generated pipeline that is best-in-class and a renewed focus on cost control give him greater conviction on the name. The analyst has an Outperform rating on Regeneron's shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Regenerative Medicine Foundation to hold a summit » 04:55
01/22/20
01/22
04:55
01/22/20
04:55
ABC

AmerisourceBergen

$91.24 /

+0.18 (+0.20%)

, ATHX

Athersys

$1.28 /

+0.01 (+0.79%)

, BLUE

Bluebird Bio

$95.90 /

-2.17 (-2.21%)

, CLBS

Caladrius

$2.90 /

-0.29 (-9.09%)

, CYRX

Cryoport

$19.41 /

+0.13 (+0.67%)

, GLW

Corning

$29.72 /

-0.35 (-1.16%)

, HEMA

HemaCare

$0.00 /

+ (+0.00%)

, IOVA

Iovance Biotherapeutics

$23.65 /

-0.22 (-0.92%)

, IQV

Iqvia

$160.82 /

-0.68 (-0.42%)

, LZAGY

Lonza

$0.00 /

+ (+0.00%)

, MBIO

Mustang Bio

$4.24 /

-0.09 (-2.08%)

, MCK

McKesson

$155.27 /

-1.05 (-0.67%)

, NVO

Novo Nordisk

$61.15 /

-0.16 (-0.26%)

, NWBO

Northwest Biotherapeutics

$0.00 /

+ (+0.00%)

, SYNH

Syneos Health

$63.87 /

-0.16 (-0.25%)

, TECH

Bio-Techne

$221.53 /

+1.08 (+0.49%)

, THMO

ThermoGenesis

$4.76 /

+0.06 (+1.28%)

, TMO

Thermo Fisher

$337.38 /

-1.77 (-0.52%)

15th Annual World Stem…

15th Annual World Stem Cell Summit will be held in Miami on January 21-24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Yesterday
Conference/Events
Cantor specialty pharma analyst to hold an analyst/industry conference call » 09:01
01/21/20
01/21
09:01
01/21/20
09:01
IMMU

Immunomedics

$19.01 /

-0.3 (-1.55%)

, SGEN

Seattle Genetics

$108.99 /

+1.33 (+1.24%)

, MGNX

MacroGenics

$11.27 /

-0.34 (-2.93%)

, PBYI

Puma Biotechnology

$9.72 /

+0.83 (+9.34%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, ARVN

Arvinas

$50.96 /

-0.29 (-0.57%)

Large Cap & Specialty…

Large Cap & Specialty Pharmaceuticals Analyst Chen, along with Key Opinion Leader Timothy Pluard, Medical Director of Saint Luke's Cancer Institute, discuss the 2020 outlook in breast cancer and potential approvals in TNBC (Triple-Negative Breast Cancer) and HER2+ (Human Epidermal Growth Factor Receptor 2) on an Analyst/Industry conference call to be held on January 27 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Seattle Genetics achieves milestone following EC approval of Roche's Polivy » 08:11
01/21/20
01/21
08:11
01/21/20
08:11
SGEN

Seattle Genetics

$108.99 /

+1.33 (+1.24%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Seattle Genetics (SGEN)…

Seattle Genetics (SGEN) announced that it will receive a milestone payment from Roche (RHHBY) triggered by European Commission conditional marketing authorisation for Polivy. Polivy is an antibody-drug conjugate, or ADC, that utilizes Seattle Genetics' technology. It was developed and is commercialized by Roche/Genentech. Polivy was approved in combination with bendamustine plus MabThera for the treatment of adult patients with relapsed or refractory, or R/R, diffuse large B-cell lymphoma, or DLBCL, who are not candidates for a haematopoietic stem cell transplant. Polivy was granted Priority Medicines, or PRIME, designation by the European Medicines Agency for the treatment of people with R/R DLBCL in 2017.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Regenerative Medicine Foundation to hold a summit » 07:57
01/21/20
01/21
07:57
01/21/20
07:57
ABC

AmerisourceBergen

$91.06 /

-0.42 (-0.46%)

, ATHX

Athersys

$1.27 /

-0.015 (-1.17%)

, BLUE

Bluebird Bio

$98.07 /

+0.41 (+0.42%)

, CLBS

Caladrius

$3.19 /

-0.075 (-2.30%)

, CYRX

Cryoport

$19.28 /

+0.26 (+1.37%)

, GLW

Corning

$30.07 /

+0.05 (+0.17%)

, HEMA

HemaCare

$0.00 /

+ (+0.00%)

, IOVA

Iovance Biotherapeutics

$23.87 /

+0.13 (+0.55%)

, IQV

Iqvia

$161.50 /

+0.51 (+0.32%)

, LZAGY

Lonza

$0.00 /

+ (+0.00%)

, MBIO

Mustang Bio

$4.33 /

-0.19 (-4.20%)

, MCK

McKesson

$156.32 /

+0.07 (+0.04%)

, NVO

Novo Nordisk

$61.31 /

+0.02 (+0.03%)

, NWBO

Northwest Biotherapeutics

$0.00 /

+ (+0.00%)

, SYNH

Syneos Health

$64.03 /

+0.17 (+0.27%)

, TECH

Bio-Techne

$220.45 /

+1.18 (+0.54%)

, THMO

ThermoGenesis

$4.70 /

-0.15 (-3.09%)

, TMO

Thermo Fisher

$339.15 /

+2.34 (+0.69%)

15th Annual World Stem…

15th Annual World Stem Cell Summit will be held in Miami on January 21-24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Conference/Events
EBDF Group to hold a conference » 04:55
01/15/20
01/15
04:55
01/15/20
04:55
A

Agilent

$88.02 /

+0.565 (+0.65%)

, AGE

A.G. Edwards

$1.85 /

+0.13 (+7.56%)

, ALNY

Alnylam

$118.48 /

+3.68 (+3.21%)

, AZN

AstraZeneca

$50.18 /

+0.5 (+1.01%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BCLI

BrainStorm

$4.34 /

-0.04 (-0.91%)

, ENTX

Entera Bio

$2.78 /

-0.03 (-1.07%)

, DYAI

Dyadic International

$5.50 /

-0.135 (-2.40%)

, DTIL

Precision BioSciences

$13.40 /

-0.12 (-0.89%)

, DD

DuPont

$60.16 /

-0.25 (-0.41%)

, CYCC

Cyclacel Pharmaceuticals

$0.74 /

-0.0549 (-6.91%)

, CTLT

Catalent

$60.34 /

+0.88 (+1.48%)

, COWN

Cowen Group

$16.34 /

-0.2 (-1.21%)

, GMAB

Genmab

$22.44 /

-0.21 (-0.93%)

, IDXG

Interpace Biosciences

$0.62 /

+ (+0.00%)

, LCTX

Lineage Cell Therapeutics

$0.75 /

-0.0146 (-1.92%)

, PHIO

Phio Pharmaceuticals

$0.20 /

+0.0117 (+6.35%)

, PJC

Symbol now PIPR

$0.00 /

+ (+0.00%)

, TNXP

Tonix Pharmaceuticals

$1.48 /

+0.03 (+2.07%)

, TROV

Trovagene

$1.47 /

+0.15 (+11.41%)

, VCYT

Veracyte

$28.58 /

+0.17 (+0.60%)

, VIE

Viela Bio

$37.10 /

+4.17 (+12.66%)

, PSTV

Plus Therapeutics

$2.81 /

+0.02 (+0.72%)

, RDUS

Radius Health

$20.14 /

+1.77 (+9.64%)

, MRNA

Moderna

$20.01 /

-0.21 (-1.04%)

, MRK

Merck

$89.93 /

+0.5 (+0.56%)

, NAVB

Navidea

$1.49 /

-0.03 (-1.97%)

, NBSE

NeuBase Therapeutics

$6.31 /

-0.19 (-2.92%)

, NVO

Novo Nordisk

$59.62 /

+0.66 (+1.12%)

, NVS

Novartis

$94.47 /

+0.765 (+0.82%)

, OVID

Ovid Therapeutics

$3.59 /

+0.09 (+2.57%)

, STI

Merged to become TFC

$0.00 /

+ (+0.00%)

, XON

Intrexon

$7.20 /

+0.46 (+6.82%)

, SLRX

Salarius Pharmaceuticals

$3.20 /

+0.15 (+4.92%)

, VVUS

VIVUS

$2.72 /

-0.01 (-0.37%)

, SIVB

SVB Financial

$253.42 /

-0.36 (-0.14%)

, VRML

Vermillion

$0.79 /

-0.0453 (-5.39%)

, VKTX

Viking Therapeutics

$7.36 /

+0.045 (+0.62%)

Biotech Showcase 2020…

Biotech Showcase 2020 will be held in San Francisco on January 13-15.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Halozyme CEO says 'tremendous progress repositioning the company' » 08:06
01/14/20
01/14
08:06
01/14/20
08:06
HALO

Halozyme

$18.79 /

-0.2 (-1.05%)

, JNJ

Johnson & Johnson

$145.71 /

+0.63 (+0.43%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

"We have made…

"We have made tremendous progress repositioning the company to focus solely on driving the growth and profitability of our ENHANZE business," said Dr. Helen Torley, president and CEO. "Looking ahead, we anticipate a number of value-creating financial and ENHANZE-related milestones will be achieved during 2020." Anticipated 2020 ENHANZE Key Events: U.S. FDA decision on the approval of the Biologics License Application submitted by ENHANZE collaboration partner Janssen Biotech (JNJ) in July 2019 for Daratumumab SC. European Medicines Agency decision on the approval of the extension application submitted by Janssen-Cilag International in July 2019 for Daratumumab SC. Completion in Q1 2020 of regulatory submissions to the FDA and EMA by Roche (RHHBY) seeking approval for the fixed-dose combination of Perjeta and Herceptin utilizing ENHANZE in combination with intravenous chemotherapy. At least 3 new Phase 3 and 1 Phase 2 clinical trial initiations by ENHANZE collaboration partners. Initiation of at least five new Phase 1 clinical trials with partner products utilizing the ENHANZE drug delivery technology.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Roche to price oral SMA drug 'aggressively' to challenge rivals, Reuters reports » 06:18
01/14/20
01/14
06:18
01/14/20
06:18
RHHBY

Roche

$0.00 /

+ (+0.00%)

, BIIB

Biogen

$293.80 /

-2.76 (-0.93%)

, NVS

Novartis

$93.71 /

-0.165 (-0.18%)

Roche (RHHBY) plans to…

Roche (RHHBY) plans to price its oral spinal muscular atrophy drug risdiplam "aggressively" in order to challenge Biogen's (BIIB) Spinraza and Novartis's (NVS) gene therapy Zolgensma, two of the world's most expensive medicines, Reuters' Robin Respaut reports. Spinraza's list price is $750,000 in the first year, and $375,000 thereafter, while Novartis's gene therapy for the genetic muscle wasting disease lists at $2.1M. The FDA is due to decide on risdiplam by May 24, the report notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.